Maki Yamakawa
Papers
1
Total Citations
1
H-Index
1
About
Dr. Maki Yamakawa is a pioneering urologic oncologist whose work sits at the critical intersection of advanced robotic surgery and modern immunotherapy for renal cell carcinoma (RCC). Her primary research focuses on refining complex surgical techniques, particularly robot-assisted radical nephrectomy with inferior vena cava thrombectomy, a procedure of extreme technical difficulty. Dr. Yamakawa’s most notable contribution is demonstrating the feasibility and safety of performing this demanding surgery following neoadjuvant combination immunotherapy, specifically pembrolizumab and axitinib. Her 2024 case report, which has already garnered attention in the field, provides crucial evidence that pre-surgical immunotherapy does not preclude a successful robotic approach, potentially expanding treatment options for patients with advanced, unresectable disease. While her citation count is currently modest—a reflection of her work’s very recent publication—the clinical significance is substantial. By documenting this novel treatment sequence, Dr. Yamakawa is helping to shape a new paradigm where aggressive surgical intervention can follow powerful systemic therapy, offering renewed hope for patients facing the most challenging cases of RCC.
Research Focus
Key Achievements
Top Papers
- 1